Lupin Launches Doxercalciferol Injection

Pharma major Lupin Limited (Lupin) announced the launch of Doxercalciferol Injection, 4 mcg/2 ml (2 mcg/mL) Multi-dose Vials, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier.
Lupin’s Doxercalciferol Injection, 4 mcg/2 ml (2 mcg/ml) Multi-dose Vial s, is the therapeutic generic equivalent of Sanofi Genzyme’s Hectorol® Injection, 4 mcg/2 ml (2 mcg/ml) Multi-dose Vials. It is indicated for the treatment of secondary hyperparathyroidism in adult patients with CKD on dialysis.

Doxercalciferol injection, 4 mcg/2 ml (2 mcg/ml) Multi-dose Vials, (RLD: Hectorol®) had an annual sales of approximately USD 132 million in the U.S. (IQVIA MAT October 2019).

Shares of LUPIN LTD. was last trading in BSE at Rs.766.1 as compared to the previous close of Rs. 754. The total number of shares traded during the day was 40436 in over 1103 trades.

The stock hit an intraday high of Rs. 767.55 and intraday low of 754.1. The net turnover during the day was Rs. 30848598.-Equity Bulls